Total Payments
$301,694
2024 Payments
$6,409
Companies
18
Transactions
287
Medicare Patients
736
Medicare Billing
$141,332
Payment Breakdown by Category
Consulting$165,683 (54.9%)
Travel$61,717 (20.5%)
Other$39,687 (13.2%)
Research$29,225 (9.7%)
Food & Beverage$5,291 (1.8%)
Education$90.28 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $165,683 | 61 | 54.9% |
| Travel and Lodging | $61,717 | 83 | 20.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,687 | 30 | 13.2% |
| Unspecified | $29,225 | 11 | 9.7% |
| Food and Beverage | $5,291 | 100 | 1.8% |
| Education | $90.28 | 2 | 0.0% |
Payments by Type
General
$272,468
276 transactions
Research
$29,225
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $103,118 | 66 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $43,138 | 78 | $0 (2023) |
| Janssen Global Services, LLC | $32,050 | 20 | $0 (2022) |
| F. Hoffmann-La Roche AG | $27,258 | 24 | $0 (2020) |
| Merck Sharp & Dohme LLC | $23,221 | 28 | $0 (2024) |
| Genentech USA, Inc. | $20,913 | 11 | $0 (2021) |
| Celgene Corporation | $12,147 | 18 | $0 (2019) |
| Janssen Biotech, Inc. | $10,589 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $7,981 | 10 | $0 (2023) |
| Genentech, Inc. | $7,455 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,409 | 18 | Merck Sharp & Dohme LLC ($2,537) |
| 2023 | $24,940 | 26 | Merck Sharp & Dohme LLC ($16,415) |
| 2022 | $18,480 | 10 | Janssen Global Services, LLC ($6,820) |
| 2021 | $18,200 | 13 | AbbVie Inc. ($9,300) |
| 2020 | $44,841 | 18 | AbbVie Inc. ($18,373) |
| 2019 | $62,078 | 57 | AbbVie, Inc. ($28,884) |
| 2018 | $53,601 | 54 | AbbVie, Inc. ($18,592) |
| 2017 | $73,144 | 91 | Janssen Global Services, LLC ($20,270) |
All Payment Transactions
287 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.95 | General |
| 11/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $113.98 | General |
| Category: Hematology | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $304.88 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $131.55 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $39.98 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $785.04 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $304.88 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $147.50 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $99.99 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $62.39 | General |
| 06/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Education | In-kind items and services | $30.29 | General |
| Category: Hematology | ||||||
| 04/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 12/22/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: Oncology | ||||||
| 12/21/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $108.82 | General |
| Category: Oncology | ||||||
| 12/07/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $119.99 | General |
| Category: ONCOLOGY | ||||||
| 08/04/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $2,160.00 | General |
| Category: Oncology | ||||||
| 06/28/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| UTILITY OF MEASURABLE RESIDUAL DISEASE FOR PREDICTING TREATMENT OUTCOMES OF NOVEL TARGETED AGENTS IN PATIENTS WITH CLL | F. Hoffmann-La Roche AG | $15,447 | 1 |
| Celgene - Connect CLL | Celgene Corporation | $2,533 | 1 |
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $2,372 | 4 |
| A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSEDREFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 ABT-199 PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB | F. Hoffmann-La Roche AG | $1,616 | 1 |
| CC-5013-CLL-010 | Celgene Corporation | $1,156 | 1 |
| An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) (17004) | Celgene Corporation | $935.00 | 1 |
| CC-122-CLL-001 | Celgene Corporation | $366.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 169 | 367 | $173,558 | $38,506 |
| 2022 | 1 | 166 | 351 | $152,334 | $39,176 |
| 2021 | 1 | 166 | 370 | $163,324 | $40,142 |
| 2020 | 2 | 235 | 352 | $133,870 | $23,508 |
Total Patients
736
Total Services
1,440
Medicare Billing
$141,332
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 169 | 367 | $173,558 | $38,506 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 166 | 351 | $152,334 | $39,176 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 166 | 370 | $163,324 | $40,142 | 24.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 94 | 143 | $64,064 | $12,596 | 19.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 141 | 209 | $69,806 | $10,912 | 15.6% |
About Dr. Thomas Kipps, M.D
Dr. Thomas Kipps, M.D is a Internal Medicine healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306861950.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Kipps, M.D has received a total of $301,694 in payments from pharmaceutical and medical device companies, with $6,409 received in 2024. These payments were reported across 287 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($165,683).
As a Medicare-enrolled provider, Kipps has provided services to 736 Medicare beneficiaries, totaling 1,440 services with total Medicare billing of $141,332. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location La Jolla, CA
- Active Since 07/13/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306861950
Products in Payments
- Imbruvica (Drug) $37,691
- IMBRUVICA (Drug) $33,389
- Venclexta (Drug) $29,732
- VENCLEXTA (Drug) $23,401
- VENCLEXTA (Biological) $23,395
- DARZALEX (Biological) $20,270
- Non-Covered Product (Drug) $19,800
- Revlimid (Drug) $10,846
- KEYTRUDA (Biological) $8,945
- Rituxan (Biological) $7,575
- BRUKINSA (Drug) $4,425
- GAZYVA (Biological) $3,237
- Ibrutinib (Drug) $2,372
- CALQUENCE (Drug) $2,197
- Venclexta (Biological) $1,616
- Zydelig (Drug) $1,580
- JCAR017 (Drug) $935.00
- CC-122 (Drug) $366.60
- Yescarta (Drug) $309.08
- Empaveli (Drug) $144.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in La Jolla
Dr. Pam Taub, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Hyong Kim, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. John Rogers, M.d, M.D
Internal Medicine — Payments: $852,868
Internal Medicine $852,868
Rohit Loomba, Md, MD
Internal Medicine — Payments: $849,501
Internal Medicine $849,501
Dr. Fouad Moawad, M.d, M.D
Internal Medicine — Payments: $526,722
Internal Medicine $526,722
Dr. Brian Modena, M.d., Msc, M.D., MSC
Internal Medicine — Payments: $471,187
Internal Medicine $471,187